Commercial Opportunities from Biomarkers: Transforming Drug Discovery, Clinical Development and Molecular Diagnostics' is the Latest Addition to the Drug Discovery Series.DUBLIN Dublin, city, Republic of Ireland Dublin, Irish Baile Átha Cliath, county borough (1991 pop. 915,516), Leinster, capital of the Republic of Ireland, on Dublin Bay at the mouth of the Liffey River. , Ireland Ireland, Irish Eire (âr`ə) [to it are related the poetic Erin and perhaps the Latin Hibernia], island, 32,598 sq mi (84,429 sq km), second largest of the British Isles. -- Research and Markets (http://www.researchandmarkets.com/reports/c39111) has announced the addition of Commercial Opportunities from Biomarkers: Transforming drug discovery, clinical development and molecular diagnostics (1) Software routines that test hardware components (memory, keyboard, disks, etc.). Diagnostics are often stored in ROM chips and activated on startup. (2) Error messages in a programmer's source code that refer to statements or syntax that the compiler or assembler to their offering High clinical development costs coupled with declining drug discovery success rates have meant that pharmaceutical companies must re-evaluate their drug development process in order to reduce attrition rates Noun 1. attrition rate - the rate of shrinkage in size or number rate of attrition rate - a magnitude or frequency relative to a time unit; "they traveled at a rate of 55 miles per hour"; "the rate of change was faster than expected" and remain competitive. Over the next decade biomarkers will change the way in which pharma companies determine the economic viability of their drug discovery process. The use of biomarkers to aid the discovery of promising products will create an enhanced understanding of the clinical development process and help to facilitate the shift towards 'personalized medicine'. 'Commercial Opportunities from Biomarkers: Transforming drug discovery, clinical development and molecular diagnostics' is the latest addition to the drug discovery series, examining recent developments and applications within the biomarkers field. Using up-to-date case studies to indicate best practice strategies, this report will ensure that you are able streamline your R&D process and identify potential cost savings throughout drug discovery and development. Regulatory reg·u·late tr.v. reg·u·lat·ed, reg·u·lat·ing, reg·u·lates 1. To control or direct according to rule, principle, or law. 2. changes are analyzed an·a·lyze tr.v. an·a·lyzed, an·a·lyz·ing, an·a·lyz·es 1. To examine methodically by separating into parts and studying their interrelations. 2. Chemistry To make a chemical analysis of. 3. and recent alliances are examined, enabling you to understand the role and future of this fast-moving field. Commercial Opportunities from Biomarkers Contents are as follows:- Executive Summary Biomarkers in drug discovery, development and clinical diagnostics Regulatory acceptance of biomarkers now and in the future Fishing for new drug targets with biomarkers Biomarkers aiding go/no go In engineering and manufacturing, a go/no go (or Go-NoGo) is a process or device used in quality control. In psychology, a go/no-go test requires a participant to perform an action given certain stimuli (e.g. decisions Imaging biomarkers directing clinical dosing studies Clinical biomarkers improving trial design Biomarkers as surrogate endpoints  It has been suggested that Surrogate markers, Surrogate end point be merged into this article or section. Market size, collaborations and future directions Chapter 1 Biomarkers in drug discovery, development and clinical diagnostics Chapter 2 Regulatory acceptance of biomarkers now and in the future Chapter 3 Fishing for new drug targets with biomarkers Chapter 4 Biomarkers aiding go/no go decisions Chapter 5 Imaging biomarkers directing clinical dosing studies Chapter 6 Clinical biomarkers improving trial design Chapter 7 Biomarkers as surrogate endpoints Chapter 8 Market size, collaborations and future directions Chapter 9 Appendix List of Figures List of Tables For more information visit http://www.researchandmarkets.com/reports/c39111 |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion